Multiply Labs Inc. has entered into a pivotal collaboration with AstraZeneca to revolutionize the manufacturing process of cell therapies. This partnership aims to assess the implementation of good manufacturing practice (GMP)-ready robotic systems for large-scale production, addressing critical bottlenecks in the cell therapy landscape. Through this initiative, the focus will be on automating standard instruments prevalent in cell therapy production with Multiply Labs’ advanced robotic biomanufacturing technology.
Enhancing Manufacturing Efficiency
The primary objective of this collaboration is to facilitate scalable and high-throughput manufacturing while adhering to the stringent quality and regulatory standards essential for both clinical and commercial applications. Fred Parietti, Ph.D., the CEO of Multiply Labs, emphasized the complexity and promise of cell therapies, stating that enhancing manufacturing efficiency is crucial for broader accessibility of these innovative treatments.
The partnership with AstraZeneca represents a significant step toward evaluating and refining Multiply Labs’ multi-arm robotic clusters. This effort combines AstraZeneca’s extensive scientific and clinical expertise with Multiply Labs’ cutting-edge robotic platform, aiming to establish the next generation of GMP-ready cell therapy production systems.
Innovative Robotic Solutions
Founded in 2016, Multiply Labs has been at the forefront of automation in the pharmaceutical industry. The company specializes in developing cloud-controlled robotics designed for the scalable production of advanced therapies. Their latest systems utilize four robotic arms that work in parallel, capable of operating a diverse range of cell therapy manufacturing instruments already established within the industry. This innovative architecture minimizes the need for process alterations while maximizing output, significantly enhancing productivity in existing manufacturing facilities.
Multiply Labs boasts an impressive clientele that includes some of the largest pharmaceutical manufacturers globally. The company’s strength lies in its interdisciplinary team, which comprises mechanical engineers, electrical engineers, computer scientists, software engineers, and pharmaceutical scientists—all dedicated to pushing the boundaries of robotics in biopharma.
Previous Collaborations
This partnership with AstraZeneca is not the first for Multiply Labs in its quest to streamline cell therapy manufacturing. In September, the company joined forces with Thermo Fisher Scientific to integrate robotic solutions with Thermo Fisher’s automated Gibco CTS DynaCellect Magnetic Separation System. This system provides a closed, automated method for isolating, activating, and removing beads in cell therapy development, ensuring high purity, recovery, and viability of cells.
By collaborating with Thermo Fisher, Multiply Labs aims to expedite crucial stages in cell therapy production. The integration reduces manual interventions, thereby enhancing process consistency and overall efficiency.
Focus on Autoimmune Diseases
In June, Multiply Labs also announced a pilot collaboration with Kyverna Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing therapies for autoimmune conditions. This partnership centers on evaluating the automation of cell therapy manufacturing processes for Kyverna’s KYV-102 using Multiply Labs’ robotic systems. This initiative underscores the potential of robotic automation to significantly impact the treatment landscape for patients suffering from autoimmune diseases.
The Future of Cell Therapy
As the demand for cell therapies continues to rise, the need for efficient, scalable manufacturing solutions becomes increasingly critical. Multiply Labs’ strategic collaborations with industry giants like AstraZeneca, Thermo Fisher, and Kyverna Therapeutics highlight a shared vision of overcoming manufacturing bottlenecks and enhancing the availability of these transformative therapies.
Key Takeaways
- Multiply Labs and AstraZeneca partner to automate cell therapy manufacturing.
- The collaboration aims to implement GMP-ready robotic systems for large-scale production.
-
Multiply Labs utilizes innovative four-arm robotic systems to enhance efficiency in cell therapy manufacturing.
-
Previous collaborations with Thermo Fisher and Kyverna Therapeutics show a commitment to advancing automation in biopharma.
-
The push for scalable manufacturing solutions addresses the increasing demand for cell therapies.
In conclusion, the collaboration between Multiply Labs and AstraZeneca represents a significant advancement in the field of cell therapy manufacturing. By leveraging automation and cutting-edge technology, this partnership promises to enhance the efficiency and scalability of producing life-changing therapies. As the landscape evolves, the focus on innovation will be essential for meeting the growing needs of patients and healthcare providers alike.
Read more → www.therobotreport.com